EOLS - Evolus Inc (Healthcare: Drug Manufacturers - Specialty & Generic) | Projected Earnings Date: 2025-11-03 (Delayed quote data 2025-09-16) |
|
|
![]() |
![]() |
Company Profile | |
Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate isJeuveau, an injectable formulation of a 900 kDa Botulinum toxin Type A complex. It has also completed the development program for DWP-450 for the treatment of moderate to severe glabellar lines. |
Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |